However, a concurrent limitation with using this mouse model of metastatic human cancers is the inability to determine the efficacy of PD-1/PD-L1 blockers in combination with IFNγ or assess the role of immune cells in mediating the effects of IFNγ in combination with chemotherapy. Here, IFNG is linked to cancer.